Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI323 in advanced malignancies
NCT04916119Phase 1Unknown
- Sponsor
- Innovent Biologics
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI323 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 11 more (2 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of Adverse Events at 24 months. Status: unknown.
02
Drugs
IBI323
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04916119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916119.